Black Diamond Therapeutics Q3 net loss $23.0M; cash $144.3M; advances BDTX-1535 and BDTX-4933 trials

Black Diamond Therapeutics, Inc.

2023-Q3 EPS reported -$1.54

Net loss $23.0M vs $21.7M in Q3 2022; R&D $16.2M, G&A $7.9M (includes CEO transition costs).
Cash, cash equivalents, and investments $144.3M at Sep 30, 2023; expected to fund operations into H1 2025.
BDTX-1535 Phase 1 expansion cohorts enrolling; initial NSCLC expansion data expected 2024; GBM dose escalation data later 2023.
BDTX-4933 Phase 1 trial dosed first patient; targeting KRAS, NRAS, BRAF mutations; dose escalation ongoing.
Mark Velleca appointed President and CEO in September 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.96

Black Diamond Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 6, 2023, Black Diamond Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001701541-23-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.